News | January 30, 2026
Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The base Gland business posted ?11,790 million in revenue, up 16% YoY
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
The Unit is approved by major regulators like EMA, Europe; Health Canada, Anvisa, Brazil and TGA, Australia
The initiative aims to connect startups and tech companies with its business units,
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
Subscribe To Our Newsletter & Stay Updated
